LYVE1 and prostate neoplasm: Therefore, the expression of CD34 and LYVE-1, markers for vascular and lymphatic vessels, respectively, was also assessed in resected prostate tumors from mice treated with or without 64Cu/NOTA-βAla-R954 using IHC (Figure 5C).